Bryan Davis, MD
Otolaryngology · Colorado Springs, CONPI 1336232669
Payments from drug & device makers
Across 195 payments — averaging $7363.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$824K
- Aerin Medical Inc.$239K
- Optinose US, Inc.$115K
- AstraZeneca$84K
- Otonomy, Inc.$64K
- Stryker$42K
- plus $68K from 18 others
Across 9 payments — averaging $20,718 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurent Medical Limited$186K
What the payments were for
- Food & beverage$2,146100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 37 | $823,501 |
| Aerin Medical Inc. | 30 | $239,311 |
| Optinose US, Inc. | 14 | $114,594 |
| AstraZeneca | 39 | $84,097 |
| Otonomy, Inc. | 10 | $64,178 |
| Stryker | 17 | $42,003 |
| Eli Lilly | 2 | $21,058 |
| Insmed, Inc. | 6 | $13,070 |
| Paratek Pharmaceuticals, Inc. | 2 | $12,277 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $12,250 |
| Roche Products Limited | 5 | $6,134 |
| Intersect ENT, Inc. | 4 | $2,949 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Regeneron Healthcare Solutions, Inc. | 4 | $85 |
| Acclarent, Inc | 2 | $68 |
| Amgen | 1 | $64 |
| Sanofi | 3 | $54 |
| Pfizer | 2 | $48 |
| Genentech, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$233
- SCOPIS ENT$138
- VivAer$119
- RhinAer$119
How this compares
$1,435,943 in reported general payments places this provider in the 95th percentile of 174 otolaryngology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 178 | $4,573 |
| Fluticasone Propionate | 146 | $4,077 |
| Ipratropium Bromide | 97 | $2,366 |
| Mupirocin | 104 | $898 |
| Fluocinonide | 20 | $727 |
| Tramadol Hcl | 18 | $123 |
| Prednisone | 31 | $82 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Colorado Springs
- Barton KnoxColorado Springs$198K
- Nicholas BeckmannColorado Springs$158K
- Michael WilhelmColorado Springs$76K
- Robert KellerColorado Springs$45K
- Edgar GallowayColorado Springs$39K
- David BookColorado Springs$5K
- Cameron ToddColorado Springs$4K
- Jonathan ArnholtColorado Springs$4K
- Elycia Kazemian-MarviColorado Springs$4K
- Matthew WhineryColorado Springs$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.